Restricted accessResearch articleFirst published online 2023-5
Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance
Bladder cancer (BC) has a particular importance in Egyptian patients due to aggressive behavior and absence of prognostic markers.
Objective:
To evaluate the expression of gene and protein expression of HER2 and epidermal growth factor (EGFR) in Egyptian patients with BC and ultimately to investigate their clinical implication and prognostic significance.
Material and methods:
The study was carried out on 46 patients with urothelial bladder BC. Tissue were obtained from transurethral resection (N = 22) and radical cystectomy (N = 24) specimens. The original hematoxylin and eosin slides were re-evaluated and the formalin fixed, paraffin-embedded (FFPE) tissues which had sufficient tumor tissue (>75%) and minimal or absent tumor necrosis were selected for immunohistochemistry (IHC) and RNA extraction. Furthermore, five control biopsies were obtained from patients with cystitis. Follow-up data were retrieved from the medical records which included the treatment regimen, disease recurrence and/or progression, and survival.
Results:
EGFR and HER2 protein were overexpressed in 35% and 46% of patients respectively. EGFR was correlated with the tumor size, grade and pathological stage, with a similar trend for HER2. The recurrence rate was higher in patients with expression of any of the markers. Gene expression was significantly higher (10.6-folds) for EGFR and (21-folds) for HER2 in patients with BC in comparison to control patients. Survival analysis showed lower median disease-free survival in association with HER2 protein overexpression.
Conclusions:
Our data highlighted the prognostic significance of EGFR and HER in BC and proposed their possible use as predictive markers and potential therapeutic targets.
SungHFerlayJSiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71(3): 209–249.
2.
AldersonMGrivasPMilowskyMI, et al. Histologic variants of urothelial carcinoma: morphology, molecular features and clinical implications. Bladder Cancer2020; 6(2): 107–122.
3.
AminHAAKobaisiMHSamirRM. Schistosomiasis and bladder cancer in Egypt: truths and myths. Open Access Maced J Med Sci2019; 7(23): 4023–4029.
4.
KamatAMHahnNMEfstathiouJA, et al. Bladder cancer. Lancet2016; 388(10061): 2796–2810.
5.
TseJSinglaNGhandourR, et al. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opin Investig Drugs2019; 28(9): 757–770.
6.
BabjukMBurgerMCompératEM, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol2019; 76(5): 639–657.
7.
McConkeyDJLernerSP. SIU-ICUD consultation on bladder cancer: basic science. World J Urol2019; 37(1): 15–29.
8.
ZhaoJXuWZhangZ, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol2015; 47(1): 87–94.
9.
PaneKMirabelliPCoppolaL, et al. New roadmaps for non-muscle-invasive bladder cancer with unfavorable prognosis. Front Chem2020; 8: 600.
10.
DaherAde BoerWIEl-MarjouA, et al. Epidermal growth factor receptor regulates normal urothelial regeneration. Lab Invest2003; 83(9): 1333–1341.
11.
UllrichASchlessingerJ. Signal transduction by receptors with tyrosine kinase activity. Cell1990; 61(2): 203–212.
12.
ArteagaCLEngelmanJA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell2014; 25(3): 282–303.
13.
HsuJLHungMC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev2016; 35(4): 575–588.
14.
KiselyovABunimovich-MendrazitskySStartsevV. Key signaling pathways in the muscle-invasive bladder carcinoma: clinical markers for disease modeling and optimized treatment. Int J Cancer2016; 138(11): 2562–2569.
15.
RoseMMaurerAWirtzJ, et al. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Oncogene2020; 39(44): 6856–6870.
16.
WolffACHammondMEHAllisonKH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol2018; 36(20): 2105–2122.
17.
JanjigianYYMaronSBChatilaWK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol2020; 21(6): 821–831.
18.
KissBWyattAWDouglasJ, et al. Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy. Sci Rep2017; 7: 42713.
19.
AgrawalVBhartiNPandeyR. Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: identification of patients for targeted therapy. Arab J Urol2020; 18(4): 267–272.
20.
QuesnelleKMGrandisJR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res2011; 17(18): 5935–5944.
21.
TsaiYCHoPYTzenKY, et al. Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Mol Cancer Ther2015; 14(3): 810–820.
22.
CarlssonJWesterKDe La TorreM, et al. EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. Radiol Oncol2015; 49(1): 50–58.
23.
CormioLSanguedolceFCormioA, et al. Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget2017; 8(15): 25433–25441.
24.
MaherSKoliebESabikNA, et al. Comparison of the osteogenic differentiation potential of mesenchymal cells isolated from human bone marrow, umbilical cord blood and placenta derived stem cells. Beni-Suef Univ J Appl Sci2015; 4: 80–85.
25.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods2001; 25(4): 402–408.
26.
MemonAASorensenBSMeldgaardP, et al. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer2006; 94(11): 1703–1709.
27.
El-SerafiATOreffoRORoachHI. Epigenetic modifiers influence lineage commitment of human bone marrow stromal cells: differential effects of 5-aza-deoxycytidine and trichostatin A. Differentiation2011; 81(1): 35–41.
28.
ChengJHuangHZhangZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res2002; 62(14): 4157–4163.
29.
WeinsteinJNAkbaniRBroomBM, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014; 507(7492): 315–322.
30.
KhaledHMBahnassyAARaafatAA, et al. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC Cancer2009; 9: 32.
31.
BadawyAAEl-HindawiAHammamO, et al. Expression of epidermal growth factor receptor and transforming growth factor alpha in cancer bladder: schistosomal and non-schistosomal. Curr Urol2017; 9(4): 192–201.
32.
SjödahlGErikssonPLiedbergF, et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol2017; 242(1): 113–125.
33.
HashmiAAHussainZFIrfanM, et al. Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. BMC Urol2018; 18(1): 59.
34.
LaéMCouturierJOudardS, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol2010; 21(4): 815–819.
35.
El OchiMROukabliMBouaitiE, et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clin Pathol2017; 17: 3.
36.
ErikssonPSjödahlGChebilG, et al. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. Oncotarget2017; 8(30): 48905–48914.
37.
BellmuntJWernerLBamiasA, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med2015; 4(6): 844–852.
38.
NedjadiTAl-MaghrabiJAssidiM, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer2016; 16: 653.
39.
YoussefRFvon RundstedtFCKapurP, et al. Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma. J Urol2015; 193(2): 451–456.
40.
ColquhounAJMellonJK. Epidermal growth factor receptor and bladder cancer. Postgrad Med J2002; 78(924): 584–589.
41.
KassoufWBlackPCTuziakT, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol2008; 179(1): 353–358.
42.
NuttJEMellonJKQureshiK, et al. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer1998; 78(2): 215–220.
43.
GanKGaoYLiuK, et al. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis. Front Oncol2021; 11: 653491.
44.
SimonRAtefyRWagnerU, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer2003; 107(5): 764–772.
45.
SimonettiSRussoRCianciaG, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol2009; 17(3): 198–205.
46.
BolenzCShariatSFKarakiewiczPI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int2010; 106(8): 1216–1222.
47.
HammamONourHHMosaadM, et al. The clinical significance of HER2 protein amplification/expression in urinary bladder lesion. Arab J Urol2015; 13(2): 146–152.
48.
FleischmannARotzerDSeilerR, et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol2011; 60(2): 350–357.
49.
KostiIJainNAranD, et al. Cross-tissue analysis of gene and protein expression in normal and cancer tissues. Sci Rep2016; 6: 24799.
50.
CanerVTurkNSDuzcanF, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res2008; 14(3): 261–266.
51.
ChenPCYuHJChangYH, et al. HER2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol2013; 66(2): 113–119.
52.
KrügerSWeitschGBüttnerH, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer2002; 102(5): 514–518.
53.
Di MaidaFMariAScalici GesolfoC, et al. Epidermal growth factor receptor (EGFR) cell expression during adjuvant treatment after transurethral resection for non-muscle-invasive bladder cancer: a new potential tool to identify patients at higher risk of disease progression. Clin Genitourin Cancer2019; 17(4): e751–e758.
PopovZGil-Diez-De-MedinaSRaveryV, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol2004; 22(2): 93–101.
56.
ChowNHChanSHTzaiTS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res2001; 7(7): 1957–1962.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
